AU2011247995B2 - Pharmaceutical compositions and methods of making same - Google Patents

Pharmaceutical compositions and methods of making same Download PDF

Info

Publication number
AU2011247995B2
AU2011247995B2 AU2011247995A AU2011247995A AU2011247995B2 AU 2011247995 B2 AU2011247995 B2 AU 2011247995B2 AU 2011247995 A AU2011247995 A AU 2011247995A AU 2011247995 A AU2011247995 A AU 2011247995A AU 2011247995 B2 AU2011247995 B2 AU 2011247995B2
Authority
AU
Australia
Prior art keywords
dnm
pazopanib
cyclodextrin
pharmaceutical composition
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011247995A
Other languages
English (en)
Other versions
AU2011247995A1 (en
Inventor
Manish K. Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011247995A1 publication Critical patent/AU2011247995A1/en
Assigned to GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED reassignment GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED Request for Assignment Assignors: GLAXO WELLCOME MANUFACTURING PTE LTD
Application granted granted Critical
Publication of AU2011247995B2 publication Critical patent/AU2011247995B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2011247995A 2010-05-05 2011-05-05 Pharmaceutical compositions and methods of making same Ceased AU2011247995B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05
US61/331,715 2010-05-05
PCT/US2011/035363 WO2011140343A1 (en) 2010-05-05 2011-05-05 Pharmaceutical compositions and methods of making same

Publications (2)

Publication Number Publication Date
AU2011247995A1 AU2011247995A1 (en) 2012-12-13
AU2011247995B2 true AU2011247995B2 (en) 2014-07-31

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011247995A Ceased AU2011247995B2 (en) 2010-05-05 2011-05-05 Pharmaceutical compositions and methods of making same

Country Status (26)

Country Link
US (3) US20120028918A1 (enExample)
EP (1) EP2566331B1 (enExample)
JP (1) JP5835717B2 (enExample)
KR (1) KR20130071434A (enExample)
CN (1) CN102970871A (enExample)
AR (1) AR081364A1 (enExample)
AU (1) AU2011247995B2 (enExample)
BR (1) BR112012028291A2 (enExample)
CA (1) CA2798386A1 (enExample)
CL (1) CL2012003075A1 (enExample)
CO (1) CO6640262A2 (enExample)
CR (1) CR20120556A (enExample)
DO (1) DOP2012000281A (enExample)
EA (1) EA201291168A1 (enExample)
ES (1) ES2519615T3 (enExample)
IL (1) IL222751A0 (enExample)
MA (1) MA34286B1 (enExample)
MX (1) MX2012012837A (enExample)
NZ (1) NZ603411A (enExample)
PE (1) PE20130217A1 (enExample)
PH (1) PH12012502159A1 (enExample)
SG (1) SG185087A1 (enExample)
TW (1) TW201206908A (enExample)
UY (1) UY33367A (enExample)
WO (1) WO2011140343A1 (enExample)
ZA (1) ZA201208265B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
AU2013228148B2 (en) * 2012-03-08 2016-07-14 Samsung Electronics Co., Ltd. Method for controlling service in radio communication system
EP2968113B8 (en) * 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
US11136625B2 (en) 2013-08-28 2021-10-05 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
KR20170040798A (ko) * 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
EP3217924B1 (en) 2014-11-10 2025-07-16 ForSight Vision4, Inc. Expandable drug delivery devices
US11129900B2 (en) 2014-12-25 2021-09-28 Kyoto University Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
CN110769853B (zh) * 2017-04-17 2022-06-03 北京生命科学研究所 治疗雄性衰老
TWI770246B (zh) * 2017-08-02 2022-07-11 昊運股份有限公司 新穎化合物及包含其之醫藥組成物
US12109308B2 (en) * 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304694A1 (en) * 2006-01-27 2009-12-10 Amgen Inc. Ang2 and Vegf Inhibitor Combinations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
EP1968594B1 (en) * 2005-11-29 2010-09-29 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
NZ572226A (en) * 2006-04-18 2011-05-27 Ekr Therapeutics Inc Pre-mixed, ready-to-use IV bolus compositions comprising nicardipine and methods of use
CA2702984C (en) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
US20120232102A1 (en) * 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304694A1 (en) * 2006-01-27 2009-12-10 Amgen Inc. Ang2 and Vegf Inhibitor Combinations

Also Published As

Publication number Publication date
ES2519615T3 (es) 2014-11-07
WO2011140343A1 (en) 2011-11-10
AR081364A1 (es) 2012-08-29
EA201291168A1 (ru) 2013-06-28
ZA201208265B (en) 2013-07-31
MA34286B1 (fr) 2013-06-01
US20110281901A1 (en) 2011-11-17
KR20130071434A (ko) 2013-06-28
PE20130217A1 (es) 2013-03-21
JP2013525501A (ja) 2013-06-20
JP5835717B2 (ja) 2015-12-24
NZ603411A (en) 2014-10-31
IL222751A0 (en) 2012-12-31
EP2566331B1 (en) 2014-09-03
CL2012003075A1 (es) 2013-03-08
CN102970871A (zh) 2013-03-13
BR112012028291A2 (pt) 2015-09-15
EP2566331A1 (en) 2013-03-13
TW201206908A (en) 2012-02-16
US20150231265A1 (en) 2015-08-20
DOP2012000281A (es) 2013-05-31
AU2011247995A1 (en) 2012-12-13
CR20120556A (es) 2013-02-20
US20120028918A1 (en) 2012-02-02
PH12012502159A1 (en) 2013-02-04
EP2566331A4 (en) 2013-09-18
CO6640262A2 (es) 2013-03-22
CA2798386A1 (en) 2011-11-10
MX2012012837A (es) 2013-01-24
UY33367A (es) 2011-10-31
HK1175947A1 (en) 2013-07-19
SG185087A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
EP2566331B1 (en) Pharmaceutical compositions and methods of making same
BR112012033077B1 (pt) composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
US20130023550A1 (en) Pharmaceutical compositions and methods of making same
CN102112108A (zh) 水性医药剂型
US20150329519A1 (en) Formulations Comprising Lipoyl Compounds
KR20250024925A (ko) 수성 티카그렐러 용액, 제조 방법 및 용도
IL293541A (en) Ophthalmic preparations
ES2368758T3 (es) Formulación de argatroban que incluye un ácido como solubilizante.
CN111249229A (zh) 一种稳定的法匹拉韦注射液及其制备方法
CN102772409A (zh) 一种药物组合物
US9757394B2 (en) Spironolactone aqueous formulations
Patil et al. Formulation evaluation of extended-release solid dispersion of metformin hydrochloride
CN106061507A (zh) 包含苯海拉明的稳定的液体药物
HK1175947B (en) Pharmaceutical compositions and methods of making same
US20220305032A1 (en) Spironolactone Aqueous Compositions
JP6518658B2 (ja) システアミン組成物の分析方法
Al-Khawlani et al. In vitro quality evaluation of ten diclofenac sodium ampoule brands in Yemen
US20080139609A1 (en) Granisetron compositions
Nilay et al. Drug-loaded cellulose acetate and cellulose acetate butyrate films as ocular inserts
JP2025535828A (ja) エキノカンジン類似体の医薬組成物及びその調製方法
HK1123193B (en) Argatroban formulation comprising an acid as solubilizer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED

Free format text: FORMER APPLICANT(S): GLAXO WELLCOME MANUFACTURING PTE LTD

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER(S): GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired